Sony Music Entertainment has filed a second copyright infringement lawsuit against AI music company Udio, claiming the platform used 30,117 sound recordings without permission to train its generative AI models.
The suit marks Sony's continued legal escalation against Udio, making the music giant the only major label to refuse a licensing deal with the AI music generator.
Sony's complaint centers on alleged unauthorized copying of its catalog to develop Udio's AI training dataset. The company claims Udio systematically ingested protected recordings to build systems capable of generating music that competes with human artists and Sony's own catalog.
This second lawsuit follows Sony's initial legal action and reflects broader industry tensions over AI music generation. The Recording Industry Association of America has also pursued similar cases against other AI music platforms, framing unauthorized training data as a fundamental threat to artist rights and compensation.
Unlike Sony, other major labels—including Universal Music Group and Warner Music Group—have negotiated licensing agreements with AI music companies. These deals establish frameworks for compensating rightsholders when their music is used for model training.
Udio, backed by venture capital, positions itself as a tool for music creation that complements rather than replaces human artists. The company has defended its technology and disputed previous allegations from Sony and others.
The lawsuit adds pressure on the AI music industry to establish clearer legal and financial standards for training data. Courts will ultimately determine whether current copyright law covers AI training scenarios or whether new legislation is needed.
Sony's refusal to license with Udio signals the company's preference for litigation over negotiated terms, a strategy that may set precedent for how major labels handle future AI partnerships.
Artificial general intelligence, once defined as AI surpassing humans across most tasks, now lacks clear benchmarks among industry leaders. The shift reflects growing uncertainty about what AGI actually means.
An experimental lung disease treatment developed using artificial intelligence reversed biological aging markers in testing, according to its creator. The finding suggests the drug may have applications beyond its original purpose.
Industry leaders say designers should not fear job losses from generative AI, positioning the technology as a tool to enhance work rather than eliminate positions.
UBS is requiring artificial intelligence proficiency from new junior investment bankers and interns, making it among the first major financial institutions to explicitly mandate AI literacy in hiring.